Development and in Vitro Characterization of a Gemcitabine-Loaded MUC4-targeted Immunoliposome Against Pancreatic Ductal Adenocarcinoma

Anticancer Research - Greece
doi 10.21873/anticanres.12050
Full Text
Abstract

Available in full text

Date
Authors

Unknown

Publisher

International Institute of Anticancer Research

Related search

The Characterization of “Islet Invasion” in Pancreatic Ductal Adenocarcinoma

HPB
HepatologyGastroenterology
2018English

Cyr61/Ccn1 Regulates dCK and CTGF and Causes Gemcitabine Resistant Phenotype in Pancreatic Ductal Adenocarcinoma

Molecular Cancer Therapeutics
Cancer ResearchOncology
2019English

Targeted Delivery of Gemcitabine to Pancreatic Adenocarcinoma Using Cetuximab as a Targeting Agent

Cancer Research
Cancer ResearchOncology
2008English

MEX3A Knockdown Inhibits the Development of Pancreatic Ductal Adenocarcinoma

Cancer Cell International
Cancer ResearchOncologyGenetics
2020English

ST6Gal-I Sialyltransferase Promotes Chemoresistance in Pancreatic Ductal Adenocarcinoma by Abrogating Gemcitabine-Mediated DNA Damage

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
2017English

The Anti-Fibrotic Effect of GV1001 Combined With Gemcitabine on Treatment of Pancreatic Ductal Adenocarcinoma

Oncotarget
Oncology
2016English

Antiproliferative Effects of Monoclonal Antibodies Against (Pro)renin Receptor in Pancreatic Ductal Adenocarcinoma

Proceedings for Annual Meeting of The Japanese Pharmacological Society
2020English

Gemcitabine and Oxaliplatin (GEMOX) in Gemcitabine Refractory Advanced Pancreatic Adenocarcinoma: A Phase II Study

British Journal of Cancer
Cancer ResearchOncology
2006English

Non-Coding RNAs in Pancreatic Ductal Adenocarcinoma

Frontiers in Oncology
Cancer ResearchOncology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy